Pathstone Holdings
ABOS icon

Pathstone Holdings’s Acumen Pharmaceuticals ABOS Stock Holding History

Pathstone Holdings’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Hold
859,110
– – 0.01% 1036
2026
Q1 		$2.03M Hold
859,110
– – 0.01% 1019
2025
Q4 		$1.81M Hold
859,110
– – 0.01% 1078
2025
Q3 		$1.47M Sell
859,110
-199,421
-19% -$276K 0.01% 1198
2025
Q2 		$1.23M Sell
1,058,531
-28,000
-3% -$30.1K ﹤0.01% 1284
2025
Q1 		$1.2M Buy
1,086,531
+479,686
+79% +$685K 0.01% 1287
2024
Q4 		$1.04M Buy
606,845
+89,562
+17% +$216K ﹤0.01% 1350
2024
Q3 		$1.28M Buy
517,283
+37,060
+8% +$101K 0.01% 1233
2024
Q2 		$1.16M Buy
480,223
+42
+0% +$134 0.01% 1238
2024
Q1 		$1.94M Buy
480,181
+1,032
+0.2% +$3.89K 0.01% 918
2023
Q4 		$1.84M Buy
+479,149
New +$1.42M 0.01% 778

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Pathstone Holdings's ABOS Position: Q2 2026 in Review

Pathstone Holdings held its Acumen Pharmaceuticals (ABOS) position steady in Q2 2026 at 859,110 shares worth $2.29M. The position accounts for 0.01% of the portfolio, ranked #1036.

Pathstone Holdings first reported a position in ABOS in Q4 2023 and has held it in 11 quarters since. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Pathstone Holdings held 859,110 shares of Acumen Pharmaceuticals worth $2.29M as of Q2 2026.
  • Pathstone Holdings left its Acumen Pharmaceuticals share count unchanged in Q2 2026.
  • Acumen Pharmaceuticals made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1036 holding.
  • Pathstone Holdings first reported a position in Acumen Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.